CHLORPROMAZINE HIBENZATE

First approved in 1954

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H19ClN2S.C14H10O4
Molecular Weight	561.091
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC(=O)C1=C(C=CC=C1)C(=O)C2=CC=C(O)C=C2.CN(C)CCCN3C4=C(SC5=C3C=C(Cl)C=C5)C=CC=C4

InChI

InChIKey=YCMNZFDJNUBQCQ-UHFFFAOYSA-N

InChI=1S/C17H19ClN2S.C14H10O4/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20;15-10-7-5-9(6-8-10)13(16)11-3-1-2-4-12(11)14(17)18/h3-4,6-9,12H,5,10-11H2,1-2H3;1-8,15H,(H,17,18)

HIDE SMILES / InChI

Molecular Formula	C14H10O4
Molecular Weight	242.2268
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C17H19ClN2S
Molecular Weight	318.864
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/pro/chlorpromazine.html | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display | https://www.drugbank.ca/drugs/DB00477

Chlorpromazine is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Chlorpromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects). Additionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. Chlorpromazine has being marketed under the trade names Thorazine and Largactil among others. Chlorpromazine is used for treating certain mental or mood disorders (eg, schizophrenia), the manic phase of manic-depressive disorder, anxiety and restlessness before surgery, the blood disease porphyria, severe behavioral and conduct disorders in children, nausea and vomiting, and severe hiccups.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16867246 \| https://www.ncbi.nlm.nih.gov/pubmed/25557493 \| https://www.ncbi.nlm.nih.gov/pubmed/23919353 \| https://www.ncbi.nlm.nih.gov/pubmed/7918347	Antagonist 2778	1.0 nM [IC50]
Serotonin 2a (5-HT2a) receptor 231 Target ID: CHEMBL224 Sources: https://www.drugbank.ca/drugs/DB00477 \| https://www.ncbi.nlm.nih.gov/pubmed/23919353	Antagonist 2778	3.4 nM [IC50]
Dopamine D1 receptor 101 Target ID: CHEMBL2056 Sources: https://www.drugbank.ca/drugs/DB00477 \| https://www.ncbi.nlm.nih.gov/pubmed/7918347	Antagonist 2778	56.0 nM [Ki]
Histamine H1 receptor 315 Target ID: CHEMBL231 Sources: https://www.drugbank.ca/drugs/DB00477 \| https://www.ncbi.nlm.nih.gov/pubmed/23919353	Antagonist 2778	12.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Schizophrenia 298 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display	Primary	Approved 8429	THORAZINE Approved Use For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Launch Date 1957
Manic-depressive disease 9 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display	Primary	Approved 8429	THORAZINE Approved Use For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Launch Date 1957
Acute intermittent porphyria 7 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display	Primary	Approved 8429	THORAZINE Approved Use For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Launch Date 1957
Nausea and vomiting 19 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display	Primary	Approved 8429	THORAZINE Approved Use For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Launch Date 1957

C_max

Value	Dose	Analyte	Population
37.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
4.31 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
11.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
135 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
247 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
27.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
81.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
11.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
11.05 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.48 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.52 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
10% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4399487	unknown, unknown		CHLORPROMAZINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
75 mg 1 times / day multiple, intravenous Highest studied dose Dose: 75 mg, 1 times / day Route: intravenous Route: multiple Dose: 75 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/30558470	unhealthy, 52 years (range: 36.5-65.6 years) Health Status: unhealthy Condition: agitation Age Group: 52 years (range: 36.5-65.6 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/30558470	Sources: https://pubmed.ncbi.nlm.nih.gov/30558470
100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512	unhealthy, Elderly Patients Health Status: unhealthy Condition: Dementia-Related Psychosis Age Group: Elderly Patients Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512	Other AEs: Adverse event... Other AEs: Adverse event (grade 5) Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512
25 mg 1 times / day multiple, intramuscular Dose: 25 mg, 1 times / day Route: intramuscular Route: multiple Dose: 25 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0	unhealthy, Elderly Patients Health Status: unhealthy Condition: Dementia-Related Psychosis Age Group: Elderly Patients Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0	Other AEs: Adverse event... Other AEs: Adverse event (grade 5) Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0

AEs

AE	Significance	Dose	Population
Adverse event	grade 5	100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512	unhealthy, Elderly Patients Health Status: unhealthy Condition: Dementia-Related Psychosis Age Group: Elderly Patients Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512
Adverse event	grade 5	25 mg 1 times / day multiple, intramuscular Dose: 25 mg, 1 times / day Route: intramuscular Route: multiple Dose: 25 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0	unhealthy, Elderly Patients Health Status: unhealthy Condition: Dementia-Related Psychosis Age Group: Elderly Patients Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1737		inhibitor 1852 substrate 1217	inhibitor 1612

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1524 CYP2E1 882 P-gp 1461 BCRP 699 UGT2B10 25 OCT2 647 OATP1A2 35	CYP1A2 1054 P-gp 1537	CYP2B 32 CYP3A 129

Drug as perpetrator

Target	Modality	Activity
BCRP 773	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2637613/	mild [IC50 52.2 uM]
CYP2E1 970	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/15135088/	weak [IC50 1000 uM]
OATP1A2 35	inhibitor 3277 Sources: https://jpet.aspetjournals.org/content/352/3/552?cited-by=yes&legid=jpet%3B352/3/552	yes [IC50 12 uM]
OCT2 648	inhibitor 3277 Sources: https://pubmed.ncbi.nlm.nih.gov/19002438/	yes [IC50 14 uM]
CYP2D6 1891	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586484/	yes [IC50 20 uM]
P-gp 1650	inhibitor 3277 Sources: https://link.springer.com/article/10.1007/s00213-006-0437-9?shared-article-renderer	yes [IC50 5.8 uM]
UGT2B10 27	inhibitor 3277 Sources: https://dmd.aspetjournals.org/content/dmd/44/3/378.full.pdf#page=6 Page: 6.0	yes [IC50 79 uM]
CYP1A2 1692	inhibitor 3277 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586484/	yes [IC50 9.5 uM]
CYP2B 40	inducer 1573 Sources: https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-0773.1999.tb02018.x	yes
CYP3A 298	inducer 1573 Sources: https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-0773.1999.tb02018.x	yes

Drug as victim

Target	Modality	Activity
CYP1A2 1054	substrate 3367 Sources: https://www.longdom.org/open-access/cyp450-and-its-implications-in-the-clinical-use-of-antipsychotic-drugs-2161-1459-1000176.pdf Page: 4.0	yes
CYP2D6 1217	substrate 3367 Sources: https://www.sciencedirect.com/science/article/pii/S1110863017300228	yes
CYP3A4 1737	substrate 3367 Sources: https://www.longdom.org/open-access/cyp450-and-its-implications-in-the-clinical-use-of-antipsychotic-drugs-2161-1459-1000176.pdf Page: 4.0	yes
P-gp 1537	substrate 3367 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913737/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1647	inhibitor 1626 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1573882/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3647	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3647
ChemicalBook	CB5547531	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5547531
MolPort	MolPort-001-727-953	https://www.molport.com/shop/molecule-link/MolPort-001-727-953
ZINC	ZINC000000044027	http://zinc15.docking.org/substances/ZINC000000044027
eMolecules	730270	https://www.emolecules.com/cgi-bin/more?vid=730270

PubMed

Title	Date	PubMed
[Chronic intrahepatic cholestasis following chlorpromazine; treated using phenobarbital].	1976	1088626
The prolongation of QRS-duration resulting from delayed recovery of ventricular excitability. A new mechanism for intraventricular conduction disturbance. A preliminary note.	1976 Nov	1011369
Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.	1992	1350058
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.	1992 Sep	1416885
Impaired extrapyramidal function caused by the targeted disruption of retinoid X receptor RXRgamma1 isoform.	1999 Apr	10336693
The use of a side effect as a qualitative indicator of plasma chlorpromazine levels.	1999 Jan	10082231
Tardive dystonia induced by risperidone.	1999 Jun	10389620
Chlorpromazine-induced cholestatic liver disease with ductopenia.	2001 Jul	11669021
Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.	2001 Jul	11549212
Combination of benzo[a]phenothiazines with acyclovir against herpes simplex virus.	2001 Jul	11463529
Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias.	2001 Jul	11444585
Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines.	2001 Mar	11282269
Bipolar disorder after mefloquine treatment.	2001 May	11394195
Iatrogenic cardiopulmonary arrest during pediatric sedation with meperidine, promethazine, and chlorpromazine.	2001 Oct	11673713
Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms.	2002 May	12010767
Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii.	2003 Aug 1	12837520
QTc prolongation: chlorpromazine and high-dosage olanzapine.	2003 Jun	12866343
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.	2003 Mar	12629531
Mechanism of C2-toxin inhibition by fluphenazine and related compounds: investigation of their binding kinetics to the C2II-channel using the current noise analysis.	2003 Oct 24	14556742
[Differences in prooxidant effect of neuroleptics haloperidol and aminazine].	2003 Sep-Oct	14650217
UVA activated 8-MOP and chlorpromazine inhibit release of TNF-alpha by post-transcriptional regulation.	2004 Apr	15052360
Block of HERG human K(+) channel and IKr of guinea pig cardiomyocytes by chlorpromazine.	2004 May	15071359
Antipsychotics increase microtubule-associated protein 2 mRNA but not spinophilin mRNA in rat hippocampus and cortex.	2004 May 1	15079866
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.	2004 Oct	15083255
Oral terbutaline in the management of pharmacologically induced prolonged erection.	2004 Oct	14999218
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.	2005 May	15821958
Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates.	2005 Nov	16251329
Antipsychotic drugs inhibit the human corticotropin-releasing-hormone gene promoter activity in neuro-2A cells-an involvement of protein kinases.	2006 Apr	16205782
Effect of chlorpromazine on bone sialoprotein (BSP) gene transcription.	2006 Apr 15	16294319
Retinoid-mediated stimulation of steroid sulfatase activity in myeloid leukemic cell lines requires RARalpha and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways.	2006 Feb 1	16178010
Frequency of high-risk use of QT-prolonging medications.	2006 Jun	16178046

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Psychosis HOSPITALIZED PATIENTS: Acute Schizophrenia/Manic States: Oral: -Usual dose: 500 mg/day orally -Maximum dose: 2000 mg/day Parenteral: -Usual dose: 25 mg IM once, with a subsequent 25 to 50 mg injection in 1 hour if necessary -Maintenance dose: 400 mg IM every 4 to 6 hours until the patient is controlled Prompt Control of Severe Symptoms: Oral: -Usual dose: After an initial IM dose, 25 to 50 mg orally 3 times a day Parenteral: -Usual dose: 25 mg IV once, repeated in 1 hour if necessary Less Acutely Disturbed: Oral: -Initial dose: 25 mg orally 3 times a day -Usual dose: 400 mg/day Usual Adult Dose for Schizophrenia HOSPITALIZED PATIENTS: Acute Schizophrenia/Manic States: Oral: -Usual dose: 500 mg/day orally -Maximum dose: 2000 mg/day Parenteral: -Usual dose: 25 mg IM once, with a subsequent 25 to 50 mg injection in 1 hour if necessary -Maintenance dose: 400 mg IM every 4 to 6 hours until the patient is controlled Prompt Control of Severe Symptoms: Oral: -Usual dose: After an initial IM dose, 25 to 50 mg orally 3 times a day Parenteral: -Usual dose: 25 mg IV once, repeated in 1 hour if necessary Less Acutely Disturbed: Oral: -Initial dose: 25 mg orally 3 times a day -Usual dose: 400 mg/day

Route of Administration: Other

In Vitro Use Guide

Chlorpromazine inhibited the serotonin2-mediated excitation of the interneurons of rat piriform cortex with an IC50 of 14 uM.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 05:50:36 GMT 2023` Edited by `admin` on `Sat Dec 16 05:50:36 GMT 2023`
Record UNII	657G38Q829
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CHLORPROMAZINE HIBENZATE

Common Name

English

CHLORPROMAZINE HIBENZATE [JAN]

Common Name

English

Chlorpromazine hibenzate [WHO-DD]

Common Name

English

BENZOIC ACID, O-(P-HYDROXYBENZOYL)-, COMPD. WITH 2-CHLORO-10-(3-(DIMETHYLAMINO)PROPYL)PHENOTHIAZINE

Common Name

English

BENZOIC ACID, O-(P-HYDROXYBENZOYL)-, SALT WITH 2-CHLORO-10-(3-DIMETHYLAMINOPROPYL)PHENOTHIAZINE

Common Name

English

BENZOIC ACID, O-(P-HYDROXYBENZOYL)-, COMPD. WITH 2-CHLORO-10-(3-(DIMETHYLAMINO)PROPYL)PHENOTHIAZINE (1:1)

Common Name

English

BENZOIC ACID, 2-(4-HYDROXYBENZOYL)-, COMPD. WITH 2-CHLORO-N,N-DIMETHYL-10H-PHENOTHIAZINE-10-PROPANAMINE (1:1)

Common Name

English

Code System Code Type Description

ChEMBL

CHEMBL71